Loading...
•
Mar 31, 2022
Boston Scientific Q1 2022 Earnings Report
Boston Scientific's first quarter 2022 results were announced, demonstrating growth driven by strong execution, portfolio innovation, and improved procedure volume.
Key Takeaways
Boston Scientific reported net sales of $3.026 billion for the first quarter of 2022, representing a 10.0% increase on a reported basis and an adjusted EPS of $0.39. The company's growth was fueled by strong execution, an innovative portfolio, and improved procedure volume.
Net sales reached $3.026 billion, a 10.0% increase reported.
GAAP net income available to common stockholders was $0.07 per share.
Adjusted EPS was $0.39 per share.
Net sales growth was achieved across all reportable segments.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
Latin America & Canada Revenue
CapyFin.com Forward Guidance
The company estimates net sales growth for the full year 2022 to be in the range of approximately 7 to 9 percent on a reported basis, and EPS on a GAAP basis in a range of $0.78 to $0.88 and estimates adjusted EPS of $1.74 to $1.79. For the second quarter of 2022, the company estimates net sales growth to be in a range of approximately 3 to 6 percent on a reported basis and EPS on a GAAP basis in a range of $0.19 to $0.23 and adjusted EPS of $0.41 to $0.43.
Positive Outlook
- Full year 2022 net sales growth is estimated to be in a range of 7 to 9 percent on a reported basis.
- Full year 2022 organic net sales growth is estimated to be in a range of approximately 6.5 to 8.5 percent.
- Full year 2022 EPS on a GAAP basis is estimated in a range of $0.78 to $0.88.
- Full year 2022 adjusted EPS is estimated in a range of $1.74 to $1.79.
- Second quarter 2022 net sales growth is estimated to be in a range of approximately 3 to 6 percent on a reported basis.
Challenges Ahead
- Second quarter 2022 organic net sales growth is estimated to be in a range of approximately 3 to 6 percent.
- Second quarter 2022 EPS on a GAAP basis is estimated in a range of $0.19 to $0.23.
- Second quarter 2022 adjusted EPS is estimated in a range of $0.41 to $0.43.
- Full year organic net sales guidance excludes the impact of foreign currency fluctuations
- Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations
Revenue & Expenses
Visualization of income flow from segment revenue to net income